Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo

International Journal of Biological Markers

Volumn 21, Issue 4, 2006, Pages 218-222

  Schmidmaier, Ralf ^a   Morsdorf K ^a   Baumann, P ^a   Emmerich, B ^a   Meinhardt, G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Adhesion; Drug resitance; ICAM 1; LFA 1; Multiple myeloma; VCAM; VLA 4

Indexed keywords

CD38 ANTIGEN; CELL ADHESION MOLECULE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; INTERCELLULAR ADHESION MOLECULE 1; MELPHALAN; PROTEIN ANTIBODY; SYNDECAN 1; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RESISTANCE; CELL ADHESION; CELL SELECTION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION;

EID: 33846542647     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2008.1098     Document Type: Article

References (9)

1. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-67.
2. Schmidmaier R, Baumann P, Simsek M, Dayyani F, Emmerich B, Meinhardt G. The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. Blood 2004; 104: 1825-32.
3. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood 2004; 103: 2332-6.
4. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol 1995; 50: 9-14.
5. Ahsmann EJ, Lokhorst HM, Dekker AW, Bloem AC. Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 1992; 79: 2068-75.
6. Tatsumi T, Shimazaki C, Goto H, et al. Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 1996; 87: 837-42.
7. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004; 121: 482-8.
8. Alexandrakis MG, Passam FH, Sfiridaki A, et al. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines. Int J Biol Markers 2004; 19: 52-7.
9. Nishinarita S, Shimada H, Ito T, et al. Expression of beta 1 integrins (very late antigens-4 and -5) on myeloma cells and clinical correlates in patients with multiple myeloma. J Int Med Res 1998; 26: 37-42.